Trending Stocks: Paragon Offshore PLC (PGN), Idera Pharmaceuticals Inc (IDRA), And StemCells Inc (STEM)

Posted by Nathan Alexander January 5, 2015 0 Comment 1057 views

New York, NY – GDP INSIDER  – 01/05/2014.

Paragon Offshore PLC (NYSE:PGN) disclosed that it has about $35 million left to shore up its balance sheet through debt retirement. The company’s board had approved $100 million to help with paying down of debts, especially through the repurchase of senior notes. In a recent development, the company revealed repurchasing $25.2 million in principal amount under its senior unsecured notes last month.

With unfavorable oil price environment, Paragon Offshore PLC (NYSE:PGN) is keen to shore up its balance sheet and position itself for growth when the price situation improves. The company expects to record some gains with regards to debt retirement in its 4Q.

Will PGN Continue To Trend Higher Or Are Things About To Crash? See What’s Coming Up Next For PGN With A Complimentary Trend Analysis Report

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is anticipated to have a great year in 2015 based on various positive drug development projects. First, the company received FDA orphan drug designation for its drug candidate designed to combat Waldenstrom’s macroglobulinemia, the moved has increased investor attention in the stock given its potential.

The FDA issued orphan drug designation for IMO-8400, and the designation comes with various benefits. Such include longer marketing exclusivity period and support through the development and review process of the drug.

Although there are potentially good things ahead for Idera Pharmaceuticals Inc (NASDAQ:IDRA), the company might want to improve its cash position to fund its current activities. However, without a partnership, stock dilution may be inevitable.

Is IDRA Going To Continue To Move Higher Or Are Things About To Turn Around? See What’s In Store For IDRA With A Free Trend Report.

It remains to be seen whether StemCells Inc (NASDAQ:STEM) can heal itself following the pulling of a $19.3 million loan from it. In what is turning out to be a controversial move, the California Institute for Regenerative Medicine (CIRM) pulled a funding for Alzheimer’s disease program. The move is attributed to the failure by StemCells to hit a certain milestone.

StemCells Inc (NASDAQ:STEM) had received about $3.8 million from CIRM in initial funding. The final amount of the 10-year loan that is yet to be determined is expected to be forgiven.

The exit of CIRM from funding of StemCells Inc (NASDAQ:STEM) comes in the wake of CIRM’s President, Alan Trounson, joining the board of StemCells.

Will STEM Continue To Move Higher Or Are Things About To Reverse? See What Is Next For STEM With A Free Trend Analysis

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment